In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Vigorous physical activity may preserve cognitive function in high-risk HTN
Jun 24, 2024
High versus low vigorous physical activity was linked to a lower risk of mild cognitive impairment, probable dementia and MCI/probable dementia in a multivariate model.
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
Dementia with Lewy bodies risk down with α-1 adrenergic receptor antagonists
Jun 19, 2024
The risk for developing dementia with Lewy bodies was lower for men newly started on Tz/Dz/Az compared with those taking tamsulosin or 5ARI.
Lifestyle intervention can improve cognition, function in early Alzheimer’s disease
Jun 13, 2024
A significant correlation was seen between lifestyle and both cognitive function and Aβ42/40 ratio.
Tau PET performs well in predicting dementia in individuals with MCI
Jun 12, 2024
Tau positron emission tomography predicts all-cause dementia and Alzheimer disease dementia